Regeneron Pharmaceuticals vs Vertex Pharmaceuticals
REGN and VRTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How REGN and VRTX compare
Vertex Pharmaceuticals is the larger company, worth 1.5 times as much as Regeneron Pharmaceuticals ($142B against $95.5B).
On earnings, Regeneron Pharmaceuticals is cheaper: it trades at 20.5× trailing earnings, against 32.5× for Vertex Pharmaceuticals.
Regeneron Pharmaceuticals grew revenue faster over the last twelve months (18.6% versus 10.2% for Vertex Pharmaceuticals).
Vertex Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 35.0% compared with 28.5% at Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals pays a dividend yielding 0.40%; Vertex Pharmaceuticals does not pay one.
Regeneron Pharmaceuticals scores higher on the StockData Score (17 against 15 for Vertex Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | REGN | VRTX |
|---|---|---|
| Size and price | ||
| Market cap | $95.5B | $142B |
| Share price | $927.89 | $558.88 |
| Change, 1 year | 42.1% | 34.0% |
| Change, 5 years | 51.7% | 190% |
| Beta (5Y) | 0.64 | 0.54 |
| Employees | 15K | 600K |
| StockData Score | ||
| Total score | 17 (better) | 15 |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 | 3 |
| Performance score | 4 | 6 (better) |
| Health score | 6 | 6 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 20.5× (better) | 32.5× |
| P/S | 5.7× (better) | 11.3× |
| P/B | 2.9× (better) | 7.0× |
| EV/EBITDA | 16.4× (better) | 26.8× |
| P/FCF | 25.0× (better) | 37.3× |
| PEG | 7.41 | 5.32 (better) |
| FCF yield | 4.0% (better) | 2.7% |
| Fair value | $851.58 | $407.96 |
| Margin of safety | −9.0% (better) | −37.0% |
| Growth | ||
| Revenue growth (TTM) | 18.6% (better) | 10.2% |
| Revenue growth, 5Y average | 11.0% | 14.1% (better) |
| Net income growth (TTM) | 5.2% | 21.1% (better) |
| EPS growth (TTM) | 8.4% | 22.4% (better) |
| EPS growth, 5Y average | 6.3% | 8.3% (better) |
| Profitability | ||
| Gross margin | – | 86.0% |
| Operating margin | 28.8% | 38.0% (better) |
| Net margin | 28.5% | 35.0% (better) |
| FCF margin | 22.6% | 30.2% (better) |
| Return on equity | 14.9% | 23.5% (better) |
| Return on invested capital | 16.3% | 34.4% (better) |
| Financial health | ||
| Debt / equity | 0.06 (better) | 0.00 |
| Net debt / EBITDA | −1.36 | – |
| Interest coverage | 104× | – |
| Current ratio | 3.35 (better) | 3.19 |
| Altman Z-score | 7.64 | 14.06 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.40% | – |
| Payout ratio | 8.0% | – |
| Buyback yield | 2.1% (better) | 1.4% |
| Shareholder yield | 2.5% (better) | 1.4% |
| Ownership | ||
| Held by institutions | 89.0% | 95.6% |
| Held by insiders | 3.8% | 0.23% |
| Insider net buying, 12 months | −$8.7M (better) | −$158M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 2.2% | 1.8% |
Go deeper
- REGN stock overview
- REGN income statement
- REGN valuation and score
- VRTX stock overview
- VRTX income statement
- VRTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.